National evaluation about the diagnosis of activated protein C resistance;Evaluación nacional del diagnóstico de la resistencia a la proteína C activada

Revista de Investigacion Clinica

Volumn 55, Issue 3, 2003, Pages 358-369

  Montiel Manzano, Guadalupe ^a   de la Peña Díaz, Aurora ^b   Majluf Cruz, Abraham ^c   Cesarman Maus, Gabriela ^d   Corona de la Peña, Norma ^c   Cruz Cruz, Donají ^e   Gaminio, Elizabeth ^f   Martínez Murillo, Carlos ^c   Mayagoitia, Teresa ^g   Miranda Peralta, Enrique ^f   Poblete, Teresita ^c   Quintana Martínez, Sandra ^c   Ramírez, Raúl ^h   Razo, Daniel ⁱ   Ruiz de Chávez Ochoa, Adriana ^c   Reyes Núñez, Aurelia Virginia ^e   Salazar, Rosario ^g   Vicencio Santiago, Guadalupe Virginia ^c   Villa, Rosario ^d  

^a HOSPITAL DE ESPECIALIDADES   (Mexico)

^b Laboratorio de Farmacologia   (Mexico)

^c INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^d INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^e Laboratorios Clinicos de Puebla   (Mexico)

^f HOSPITAL GENERAL DE MÉXICO   (Mexico)

^g Laboratorio Hematología   (Mexico)

^h Laboratorio Carpermor   (Mexico)

ⁱ AMERICAN BRITISH COWDRAY MEDICAL CENTER   (Mexico)

Author keywords

Activated protein C resistance; FV Leiden; Protein C; Thrombophilia; Thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; NUCLEOTIDE; PROCOAGULANT;

ACTIVATED PROTEIN C RESISTANCE; ANTICOAGULATION; ARTICLE; BLOOD SAMPLING; CAUSE OF DEATH; CLINICAL LABORATORY; HEMOSTASIS; HETEROZYGOTE; HIGH RISK PATIENT; HOMOZYGOTE; HUMAN; MEXICO; MORBIDITY; MORTALITY; POINT MUTATION; PUBLIC HEALTH; QUALITY CONTROL; SCREENING TEST; SENSITIVITY AND SPECIFICITY; THROMBOPHILIA; THROMBOPLASTIN TIME; THROMBOSIS; VEIN THROMBOSIS;

ACTIVATED PROTEIN C RESISTANCE; DNA MUTATIONAL ANALYSIS; FACTOR V; GENOTYPE; LABORATORIES; MASS SCREENING; MEXICO; POLYMERASE CHAIN REACTION; QUALITY CONTROL; THROMBOPHILIA;

EID: 0042914627     PISSN: 00348376     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Lobato-mendizábal E, majluf-Cruz A. Trombofilia, tromboembolia y el uso de las heparinas no fraccionadas y de bajo peso molecular. Rev Invest Clin 2000; 52: 529-45.
2. Bick RL, Fareed J. Current status of thrombosis: A multidisciplinary medical issue and major American health problem- Beyond the year 2000. Clin Appl Thromb Hemost 1997; 3(Suppl l): S1-S5.
3. ACC/AHA Guidelines for the management of patients with acute myocardial infarction. J Am Coll Cardiol 1996; 28: 1328-428.
4. Gross JS, neufeld RR, Lobow LS, Gerber I, Rodstein M. Autopsy studies of the elderly institutionalized patients: review of 234 autopsis. Arch Intern Med 1988; 148: 173-6.
5. Lindblad B, Sternby NH, Berqvist D. Incidence of venous thromboembolism verified by necropsy over 30 years. Br Med J 1991; 302: 709-11.
6. Cade JF. High risk of the critically ill for venous thromboembolism. Crit Care Med 1982; 10: 448-50.
7. Dirección de Prestaciones Médicas del Instituto Mexicano del Seguro Social: reporte anual de morbimotalidad 1994.
8. Esmon CT. The regulation of natural anticoagulant pathways. Science 1987; 235: 1348-52.
9. Gladson CL, Scharrer I, Hach V, Beck KH, Griffin JH. The frequency of type I heterozygous protein S and protein C deficiency in 141 unrelated young patients with venous thrombosis. Thromb Haemost 1988; 59: 18-22.
10. Malm J, Laurell M, Nilsson IM, Dahlbäck B. Thromboembolic disease-critical evaluation of laboratory investigation. Thromb Haemost 1992; 68: 7-13.
11. De Stefano V, Finazzi G, Mannucci P. Inherited thrombophilia: Pathogenesis clinical syndromes, and management. Blood 1996; 87: 3531-44.
12. Dahlbäck B, Carlsson M, Svensson PJ. Familial thombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-8.
13. Griffin JH, Evatt B, Wideman C, Fernandez JA. Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood 1993; 82: 1989-93.
14. Koster T, Rosendaal FR, de Ronce H, Briet E, Vandenbroucke JP, Bertina R. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden thrombophilia study. Lancet 1993; 342: 1503-6.
15. Price DT, Ridker PM. Factor V Leiden Mutation and the risks for thromboembolic disease: as clinical perspective. Ann Intern Med 1997; 127: 895-903.
16. Laffen M, Tuddenham E. Assessing thrombotic risk. Br J Med 1998; 317: 520-3.
17. Voorberg J, Roelse J, Koopman R, Büller H, Berends F, ten Cate JW, Mertens K, van Mourik JA. Association of idiopathic venous thromboembolism with single point-mutation at Arg-506 of factor V. Lancet 1994; 343: 1535-6.
18. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995; 346: 1133-4.
19. Ridker PM, Miletich JP, Hennekens CH, Buring JE. Ethnic distribution of factor V Leiden in 4047 men and women: implications for venous thromboembolism screening. JAMA 1997; 277: 1305-7.
20. Montes MA, Fox EA, Longtine JA, Dorfman DM. Comparison of functional testing for resistance to activated protein C and molecular biological testing for factor V R506Q in 370 patients. Arch Pathol Lab Med 1998; 122: 325-9.
21. Akhtar M, Blair A, King TC, Sweeney JD. Whole blood screening test for factor V Leiden using a Russell viper venom time-based assay. Am J Clin Pathol 1998; 109: 387-91.
22. Bertina RM. Factor V Leiden and other coagulation factor mutations affecting thrombotic risk. Clin Chem 1997; 43: 1678-83.
23. de Ronde H, Bertina RM. Laboratory diagnosis of APC-resistance: a critical evaluation of the test and the development of diagnostic criteria. Thromb Haemost 1994; 72: 880-6.
24. Arkel YS, Ku D-H, Kamiyama M, Pajaro R, Alder H, Marchand A. Highly specific functional test for factor V Leiden: a modified tissue factor assay for activated protein C resistance. Haemostasis 1997; 27: 290-304.
25. Wasserman LM, Edson R, Key NS, Chibbar R, McGlennen RC. Detection of the factor V Leiden mutation: development of a testing algorithm combining a coagulation assay and molecular diagnosis. Am J Clin Pathol 1997; 108: 427-33.
26. Saiki RK, Scharf S, Faloona F, Mullis KB, Horn GT, Erlich HA, Arnheim N. Enzimatic amplification of b-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. Science 1985; 230: 1350-4.
27. Blin N, Stafford DW. A general methold for isolation of high molecular weight DNA from eukariotes. Nucleic Acids Res 1976; 3: 2303-8.
28. Rosas-Cabral A, Ayala-Sánchez, Vela-Ojeda J, Rodriguez E, Martínez M, González-Llaven J, et al. Analysis of the clinical relevance of the type of chimeric DNA in CML in one mexican population. Cancer Res Ther Cont 1999; 10: 73-80.
29. Kwok S, Mack DH, Mullis KB, Poiesz B, Ehrlich G, Blair D. Friedman-Kien A, Sninski JJ. Identification of human immuno-deficiency virus sequences by using in vitro enzimatic amplification oligomer cleavage detection. J Virol 1987; 61: 1690-4.
30. Higuchi R, von Beroldingen CH, Sensabaugh GF, Erlich HA. DNA typing 1 from single hairs. Nature 1988; 332: 543-6.
31. Li H, Gyllensten UB, Cui X, Saiki RK, Erlich HA, Arnheim N. Amplification and analysis of DNA sequences in single human sperm and diploid cells. Nature 1988; 335: 414-17.
32. Zöller B, Dahlbäck B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet 1994; 343: 1536-8.
33. Adcock DM, Fink L, Marlar RA. A laboratory approach to the evaluation of hereditary hypercoagulability. Am J Clin Pathol 1997; 108: 434-49.
34. Ruiz-Argüelles GJ, González-Estrada S, Garcés-Eisele J, Ruiz-Argüeles A. primary thrombophilia in Mexico: a prospective study. Am J Hematol 1999; 60: 1-5.
35. Dahlback B, Hillarp A, Rose S, Zoller B. Resistance to activated protein C, the F-V: Q506 allele, and venous thrombosis. Ann Hematol 1996; 72: 166-76.
36. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (APC-resistance). Blood 1995; 85: 1504-8.
37. Samama MM, Trossaert M, Horellou MH, Elalamy I, Conard J, Deschamps A. Risk of thrombosis in patients homozygous for factor V Leiden. Blood 1995; 86: 4700-2.
38. Zoller B, Berntsdotter A, Garcia de Frutos P, Dahlbach B. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood 1995; 85: 3518-23.
39. Ridker PM, Miletich JP, Stampfer MJ, Goldgaber SX, Lind-painter K, Hennekens CH. Factor V Leiden and recurrent idiopathic venous thromboembolism. Circulation 1995; 92: 2800-2.
40. Simioni P, Prandoni P, Lensing AWA, Scudeller A, Sardella C, Prins MH, et al. The risk of recurrent venous thromboembolism in patients with an Arg 506→aGln mutation in the gene for factor V (Factor V Leiden). N Engl J Med 1997; 336: 399-403.
41. Ridker PM, Hennekens CH, Selhub J, Miletich JP, Malinow MR, Stampfer MJ. Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risks of future venous thromboembolism. Circulation 1997; 95: 1777-82.
42. Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344; 1453-7.
43. Ridker PM, Miletich JP, Buring JE, Ariyo AA, Price DT, Manson JE, Hill JA. Factor V Leiden mutation as a risk factor for recurrent pregnancy loss. Ann Intern Med 1998; 128: 1000-3.
44. Gerhardt A, Schart RE, Beckmann MW, Struve S, Bender HG, Pillny M, Sandmann W, Zotz RB. Prothrombin and factor V mutations in women with a history of thrombosis during pregnacy and the puerperium. New Engl J Med 2000; 342: 374-80.
45. Middeldorp S, Henkens CMA, Koopman MMW, van Pampus ECM, Hamulyac K, van der Meer J, Prins MH, Buller HR. The incidence of venous thromboembolism in family members of patients with factor V Leiden mutation and venous thrombosis. Ann Intern Med 1998; 128: 15-20.
46. Bertina RM. Laboratory diagnosis of resistance to activated protein C. Thromb Haemost 1997; 478-82.
47. Rosendaal FR, Bertina RM, Reitsma PH. Evaluation of activated protein C resistance in stored plasma. Lancet 1994; 343: 1288-92.
48. Halbmayer M, Haushofer A, Schon R, Fisher M. Influence of lupus anticoagulant on a commercially available kit for APC-resistance. Thromb Haemost 1994; 72: 643-51.
49. Faioni EM, Boyer-Neumann C, Frahchi F, Wolf M, Meyer D, Mannucci PM. Another protein S functional assay is sensitive to resistance to activated protein C. Thromb Haemost 1994; 74: 643-51.
50. Tripodi A, Chantarankul V, Negri B, Mannucci P. Standardization of the APC resistance test. Effects of normalization of results by means of pooled normal plasma. Thromb Haemost 1988; 79: 564-6.